hotspot -WSS

hotspot

author：Wikipedia 2025-08-11 16:25:07 - browse：99197

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： The Harvard botanist who searched for psychedelics in the Amazon

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

Alabama IVF ruling threatens families facing fatal genetic disease

Obesity drugs seen as possible treatment for liver disease MASH

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Medicare inequities exacerbate Puerto Rico’s health disparities

New documents shed light on MD Anderson Cancer Institute feud

focus

hotspot

explore

Heart attack and stroke risk calculators need revising

NIH study of ME/CFS points to clear biological hallmarks

New air purifier tech could be key to improving indoor air quality

STAT readers on older presidents, polypills, Medicare, and more

In Memoriam: Notable people who died in 2023

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

As demand for Covid shots wanes, Moderna seeks its next success

Doctors' information doesn't help them choose wisely when sick

Alkermes shareholders re

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

hotspot

PBM reform efforts get punted in Congress

Alabama IVF ruling threatens families facing fatal genetic disease

Medicare Advantage proposed rates disappoint insurers

'Revelatory' study finds a smoking impact that remains after quitting

Biden report: The neurospychology of memory and aging

Senators start work on Medicare physician payment reform

hotspot

hotspot

focus

entertainment